JPRN-UMIN000009296已完成2 期
Combination therapy of Eribulin with Trastuzumab for HER2 positive metastatic breast cancer. - Eriblin with Trastuzumab for HER2 positive MBC.
Setouchi Breast Project0 个研究点目标入组 30 人开始时间: 2012年11月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Simultaneous or metachronous (within 5 years) double cancers. 2.Pregnant or breast-feeding women. 3. Psychiatric diseases. 4. Systemic and continuous steroid treatment. 5. with symptomatic brain metastasis 6. Uncontrolled hypertension. 7. Uncontrolled diabetes mellitus or the disease being treated by continuous insulin administration.
研究者
相似试验
已完成
不适用
Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.Breast cancerJPRN-UMIN000012018Mie University Hospital10
已完成
2 期
Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06)HER2 positive metastatic breast cancerJPRN-UMIN000010761Kurume University School of Medicine Department of Surgery30
已完成
2 期
A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancerFirst or second line therapy for advanced or recurrent HER2-positive breast cancer patients who have received taxane and trasutuzumab as adjuvant or recurrent therapy.JPRN-UMIN000012232JBCRG(Japan Breast Cancer Research Group)46
尚未招募
2 期
Phase II trial with eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancerBreast cancerJPRN-UMIN000010844The University of Tokushima graduate school30
尚未招募
2 期
Phase II study of eribulin with trasutuzumab for pretreated locally advanced / metastatic HER2-positive breast cancerlocally advanced / metastatic HER2-positive breast cancerJPRN-UMIN000012350agoya University50